ATRX News and Press, Adhera Therapeutics Inc From 07/29/21

Adhera to develop MLR-1019 (armesocarb) as a new class of drug for Parkinson’s Disease (PD), representing the only drug to address both movement and non-movement symptoms of PD Armesocarb is the active enantiomer in mesocarb, a drug marketed in Europe for 37 years for various p...

Adhera to acquire and develop MLR-1019 (armesocarb), the API in mesocarb – a drug previously sold in Europe for 37 years – for Parkinson’s Disease MLR-1019, a Phase 2-ready product, could have substantial benefits over today’s Parkinson’s drugs, incl...

Baton Rouge, LA, April 23, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera Therapeutics" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, is pleased to announce t...

Adhera Therapeutics ( OTCQB:ATRX ): Q3 GAAP EPS of -$0.27. More news on: Adhera Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

Company makes significant progress in invest-to-grow strategy RESEARCH TRIANGLE PARK, NC / ACCESSWIRE / November 14, 2019 / Adhera Therapeutics, Inc. (OTCQB:ATRX), an emerging specialty pharmaceutical company that commercializes and delivers effective, patient-centric treatment in chron...

RESEARCH TRIANGLE PARK, NC, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCQB: ATRX), a specialty pharmaceutical company leveraging technology to commercialize unique therapies and improve patient outcomes, today announced that it has terminated its previously announced of...

RESEARCH TRIANGLE PARK, NC / ACCESSWIRE / September 10, 2019 / Adhera Therapeutics, Inc. (OTCQB:ATRX), a specialty pharmaceutical company leveraging technology to commercialize unique therapies and improve patient outcomes, announced today that it has entered into a partnership with Indegen...

Co-promote will expand commercialization of Nitrolingual® Pumpspray, a Nitroglycerin Lingual Spray Nitroglycerin has been listed as one of the top 300 most prescribed drugs RESEARCH TRIANGLE PARK, NC / ACCESSWIRE / September 6, 2019 / Adhera Therapeutics, Inc. (OTCQB:ATRX), a ...

RESEARCH TRIANGLE PARK, NC, July 02, 2019 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCQB: ATRX), a specialty pharmaceutical company leveraging technology to commercialize unique therapies and improve patient outcomes, today announced that it has terminated its previously announced off...

Thinly traded specialty pharmaceutical company Adhera Therapeutics ( OTCQB:ATRX ) appoints Nancy Phelan as the new Chief Executive Officer of the Company More news on: Adhera Therapeutics, Inc., Healthcare stocks news Read more ...